Ascendis Pharma A (ASND) Interest & Investment Income (2014 - 2026)

Ascendis Pharma A has reported Interest & Investment Income for 13 years, with the latest figure at $5.3 million in Q1 2026.

• Quarterly Interest & Investment Income fell 82.58% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $288.3 million (up 42.58% YoY) and the FY2025 annual result came in at $276.3 million, up 174.53% from the prior year.
• Interest & Investment Income fell to $5.3 million in Q1 2026 per ASND's latest filing, from $213.7 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $213.7 million in Q4 2025 and troughed at $3.4 million in Q4 2022.
• A 5-year average of $43.6 million and a median of $31.1 million in 2024 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2024: Interest & Investment Income jumped 43363.99% in 2022, then slumped 91.98% in 2024.
• Over 5 years, Interest & Investment Income stood at $3.4 million in 2022, then jumped by 1090.61% to $40.1 million in 2023, then surged by 119.22% to $88.0 million in 2024, then soared by 142.79% to $213.7 million in 2025, then plunged by 97.53% to $5.3 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $5.3 million, $213.7 million, and $7.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.